FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135017544> ?p ?o ?g. }

• W2135017544 endingPage "484" @default.
• W2135017544 startingPage "476" @default.
• W2135017544 abstract "Abstract Numerous preclinical, epidemiologic, and clinical studies have suggested the benefits of vitamin D and its analogues for the prevention and treatment of cancer. However, the hypercalcemic effects have limited the use of 1α,25(OH)2D3, the hormonally active form of vitamin D. To identify vitamin D analogues with better efficacy and low toxicity, we have tested &gt;60 novel Gemini vitamin D analogues with a unique structure of two side chains for growth inhibition of breast cancer cells. Our initial studies found that some Gemini analogues are 5–15 times more active than 1α,25(OH)2D3 in growth inhibition assay. In vivo experiments were designed to study the inhibitory effect of selected Gemini vitamin D analogues against mammary carcinogenesis by using (a) an N-methyl-N-nitrosourea–induced estrogen receptor (ER)-positive mammary tumor model and (b) an MCF10DCIS.com xenograft model of ER-negative mammary tumors. Among vitamin D analogues we tested, Gemini 0072 [1α,25-dihydroxy-20S-21(3-trideuteromethyl-3-hydroxy-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-19-nor-cholecalciferol] and Gemini 0097 [1α,25-dihydroxy-20R-21(3-trideuteromethyl-3-hydroxy-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-19-nor-cholecalciferol] administration inhibited by 60% the NMU-induced mammary tumor burden compared with the NMU-treated control group, but these compounds were devoid of hypercalcemia toxicity. In an ER-negative xenograft model, Gemini 0097 significantly suppressed tumor growth without hypercalcemia toxicity. We found that the inhibitory effect of Gemini 0097 was associated with an increased level of cyclin-dependent kinase inhibitor p21 and the insulin-like growth factor binding protein 3 in both ER-positive and ER-negative mammary tumors. Our results suggest that Gemini vitamin D analogues may be potent agents for the prevention and treatment of both ER-positive and ER-negative breast cancer without hypercalcemia toxicity." @default.
• W2135017544 created "2016-06-24" @default.
• W2135017544 creator A5010768963 @default.
• W2135017544 creator A5011080195 @default.
• W2135017544 creator A5013925408 @default.
• W2135017544 creator A5017730279 @default.
• W2135017544 creator A5022420344 @default.
• W2135017544 creator A5026891481 @default.
• W2135017544 creator A5028427127 @default.
• W2135017544 creator A5034479183 @default.
• W2135017544 creator A5055140191 @default.
• W2135017544 creator A5058458204 @default.
• W2135017544 creator A5059532915 @default.
• W2135017544 creator A5071190557 @default.
• W2135017544 creator A5072563298 @default.
• W2135017544 creator A5080120427 @default.
• W2135017544 creator A5081312241 @default.
• W2135017544 date "2008-11-01" @default.
• W2135017544 modified "2023-09-28" @default.
• W2135017544 title "Gemini Vitamin D Analogues Inhibit Estrogen Receptor–Positive and Estrogen Receptor–Negative Mammary Tumorigenesis without Hypercalcemic Toxicity" @default.
• W2135017544 cites W1501688570 @default.
• W2135017544 cites W1512662047 @default.
• W2135017544 cites W1928250600 @default.
• W2135017544 cites W1963970680 @default.
• W2135017544 cites W1967542941 @default.
• W2135017544 cites W1974631544 @default.
• W2135017544 cites W1981199654 @default.
• W2135017544 cites W1981466402 @default.
• W2135017544 cites W1989034774 @default.
• W2135017544 cites W1992275613 @default.
• W2135017544 cites W1992934249 @default.
• W2135017544 cites W2003726111 @default.
• W2135017544 cites W2005879837 @default.
• W2135017544 cites W2006381191 @default.
• W2135017544 cites W2023233581 @default.
• W2135017544 cites W2027838551 @default.
• W2135017544 cites W2040546807 @default.
• W2135017544 cites W2043757927 @default.
• W2135017544 cites W2046726975 @default.
• W2135017544 cites W2050239312 @default.
• W2135017544 cites W2051692904 @default.
• W2135017544 cites W2057591273 @default.
• W2135017544 cites W2065291224 @default.
• W2135017544 cites W2069176102 @default.
• W2135017544 cites W2073679110 @default.
• W2135017544 cites W2080859080 @default.
• W2135017544 cites W2091312049 @default.
• W2135017544 cites W2093473720 @default.
• W2135017544 cites W2097255042 @default.
• W2135017544 cites W2101441882 @default.
• W2135017544 cites W2106579809 @default.
• W2135017544 cites W2107859602 @default.
• W2135017544 cites W2107978116 @default.
• W2135017544 cites W2109044849 @default.
• W2135017544 cites W2118245338 @default.
• W2135017544 cites W2126984324 @default.
• W2135017544 cites W2157109399 @default.
• W2135017544 cites W2168611920 @default.
• W2135017544 cites W2183408360 @default.
• W2135017544 cites W4211046201 @default.
• W2135017544 cites W87517145 @default.
• W2135017544 doi "https://doi.org/10.1158/1940-6207.capr-08-0084" @default.
• W2135017544 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2753526" @default.
• W2135017544 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19138995" @default.
• W2135017544 hasPublicationYear "2008" @default.
• W2135017544 type Work @default.
• W2135017544 sameAs 2135017544 @default.
• W2135017544 citedByCount "48" @default.
• W2135017544 countsByYear W21350175442012 @default.
• W2135017544 countsByYear W21350175442013 @default.
• W2135017544 countsByYear W21350175442014 @default.
• W2135017544 countsByYear W21350175442015 @default.
• W2135017544 countsByYear W21350175442016 @default.
• W2135017544 countsByYear W21350175442017 @default.
• W2135017544 countsByYear W21350175442018 @default.
• W2135017544 countsByYear W21350175442019 @default.
• W2135017544 countsByYear W21350175442020 @default.
• W2135017544 countsByYear W21350175442021 @default.
• W2135017544 countsByYear W21350175442022 @default.
• W2135017544 crossrefType "journal-article" @default.
• W2135017544 hasAuthorship W2135017544A5010768963 @default.
• W2135017544 hasAuthorship W2135017544A5011080195 @default.
• W2135017544 hasAuthorship W2135017544A5013925408 @default.
• W2135017544 hasAuthorship W2135017544A5017730279 @default.
• W2135017544 hasAuthorship W2135017544A5022420344 @default.
• W2135017544 hasAuthorship W2135017544A5026891481 @default.
• W2135017544 hasAuthorship W2135017544A5028427127 @default.
• W2135017544 hasAuthorship W2135017544A5034479183 @default.
• W2135017544 hasAuthorship W2135017544A5055140191 @default.
• W2135017544 hasAuthorship W2135017544A5058458204 @default.
• W2135017544 hasAuthorship W2135017544A5059532915 @default.
• W2135017544 hasAuthorship W2135017544A5071190557 @default.
• W2135017544 hasAuthorship W2135017544A5072563298 @default.
• W2135017544 hasAuthorship W2135017544A5080120427 @default.
• W2135017544 hasAuthorship W2135017544A5081312241 @default.
• W2135017544 hasBestOaLocation W21350175441 @default.
• W2135017544 hasConcept C121608353 @default.
• W2135017544 hasConcept C124490489 @default.

• next